🚀 VC round data is live in beta, check it out!
GemPharmatech Valuation Multiples
Discover revenue and EBITDA valuation multiples for GemPharmatech and similar public comparables like Vazyme Biotech, Suzhou Sepax Technologies, Takara Bio, Personalis and more.
GemPharmatech Overview
About GemPharmatech
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.
Founded
2017
HQ
Employees
1.6K
Website
Sectors
Financials (LTM)
EV
$1B
GemPharmatech Financials
GemPharmatech reported last 12-month revenue of $122M.
In the same LTM period, GemPharmatech generated $81M in gross profit and $22M in net income.
Revenue (LTM)
GemPharmatech P&L
In the most recent fiscal year, GemPharmatech reported revenue of $101M and EBITDA of $31M.
GemPharmatech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $122M | XXX | $101M | XXX | XXX | XXX |
| Gross Profit | $81M | XXX | $62M | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | — | XXX | $31M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 30% | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $22M | XXX | $16M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 16% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
GemPharmatech Stock Performance
GemPharmatech has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
GemPharmatech's stock price is $2.76.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 1.1% | XXX | XXX | XXX | $0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGemPharmatech Valuation Multiples
GemPharmatech trades at 8.2x EV/Revenue multiple, and 32.9x EV/EBITDA.
EV / Revenue (LTM)
GemPharmatech Financial Valuation Multiples
As of April 18, 2026, GemPharmatech has market cap of $1B and EV of $1B.
Equity research analysts estimate GemPharmatech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GemPharmatech has a P/E ratio of 50.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 8.2x | XXX | 10.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 32.9x | XXX | XXX | XXX |
| EV/EBIT | 41.7x | XXX | 56.1x | XXX | XXX | XXX |
| EV/Gross Profit | 12.4x | XXX | 16.1x | XXX | XXX | XXX |
| P/E | 50.6x | XXX | 70.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 81.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified GemPharmatech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
GemPharmatech Margins & Growth Rates
GemPharmatech's revenue in the last 12 month grew by 18%.
GemPharmatech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
GemPharmatech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (4%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 15% | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 19% | XXX | 18% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14% | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
GemPharmatech Public Comps
See public comps and valuation multiples for other Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| GemPharmatech | XXX | XXX | XXX | XXX | XXX | XXX |
| Vazyme Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Suzhou Sepax Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Takara Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Personalis | XXX | XXX | XXX | XXX | XXX | XXX |
| Oxford Nanopore Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GemPharmatech M&A Activity
GemPharmatech acquired XXX companies to date.
Last acquisition by GemPharmatech was on XXXXXXXX, XXXXX. GemPharmatech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by GemPharmatech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGemPharmatech Investment Activity
GemPharmatech invested in XXX companies to date.
GemPharmatech made its latest investment on XXXXXXXX, XXXXX. GemPharmatech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by GemPharmatech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout GemPharmatech
| When was GemPharmatech founded? | GemPharmatech was founded in 2017. |
| Where is GemPharmatech headquartered? | GemPharmatech is headquartered in China. |
| How many employees does GemPharmatech have? | As of today, GemPharmatech has over 1K employees. |
| Is GemPharmatech publicly listed? | Yes, GemPharmatech is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of GemPharmatech? | GemPharmatech trades under 688046 ticker. |
| When did GemPharmatech go public? | GemPharmatech went public in 2022. |
| Who are competitors of GemPharmatech? | GemPharmatech main competitors are Vazyme Biotech, Suzhou Sepax Technologies, Takara Bio, Personalis. |
| What is the current market cap of GemPharmatech? | GemPharmatech's current market cap is $1B. |
| What is the current revenue of GemPharmatech? | GemPharmatech's last 12 months revenue is $122M. |
| What is the current revenue growth of GemPharmatech? | GemPharmatech revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of GemPharmatech? | Current revenue multiple of GemPharmatech is 8.2x. |
| Is GemPharmatech profitable? | Yes, GemPharmatech is net-income-positive (as of the last 12 months). |
| What is the current net income of GemPharmatech? | GemPharmatech's last 12 months net income is $22M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.